Patent · US Active

3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

US11660302B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

CELGENE CORPORATION · US

Inventors

Peter Schafer · Ottersheim, DE
Lei Wu · San Diego, US
Ying Ye · Pleasanton, US

Key dates

Filing date	Mar 29, 2021
Grant date	May 30, 2023
Priority date	—
Expiry date	Mar 29, 2041

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.